WORLDWIDE HEALTHCARE TRUST PLC | RNS Reach Story | ||
| Go to market news section | ||
|
London, UK, 7 January 2020
Edison issues review on Worldwide Healthcare Trust (WWH)
Worldwide Healthcare Trust (WWH) is managed by Sven Borho and Trevor Polischuk at OrbiMed. They remain very constructive on the prospects for the global healthcare sector - despite headline risk ahead of the 2020 US presidential election - citing industry innovation, which they suggest is at 'unparalleled' levels, and has historically been an important driver of the sector's performance. Although investor concerns about drug pricing in the US remain, Borho and Polischuk say that pharma and biotech companies are 'still getting paid and are generating attractive returns'. In addition to opportunities in developed markets, they are also finding interesting investment ideas in China, due to higher product approval standards and a relaxation of listing requirements for fledgling companies.
WWH's shares regularly trade close to NAV (the board targets a maximum discount of 6%). The trust's current 0.4% premium to cum-income NAV compares with an average premium of 0.1% over the last three years, and average discounts of 0.1%, 2.0% and 4.3% over the last one, five and 10 years respectively. While WWH is managed for capital growth, it also pays regular six-monthly dividends, and currently yields 0.9%.
Click hereto view the full report.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by theFinancial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Mel Jenner, +44 (0)20 3077 5720
Sarah Godfrey, +44 (0)20 3681 2519
investmenttrusts@edisongroup.com
Learn more atwww.edisongroup.comand connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| ©2014London Stock Exchange plc. All rights reserved |
Edison issues review on Worldwide Healthcare Trust - RNS
Attachments
- Original document
- Permalink
Disclaimer
Worldwide Healthcare Trust plc published this content on 07 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 January 2020 14:47:03 UTC
